Resumen de la semana (3.30-4.3): Haier Bio sube un 1.70% en la semana, con un flujo neto total de fondos principales de 2.3269 millones de yuanes.

Star Market News, as of the close on April 3, 2026, Haier Biotech (688139) closed at 31.17 yuan, up 1.7% from last week’s 30.65 yuan. This week, Haier Biotech’s intraday high on April 1 was 32.58 yuan. The intraday low on March 30 was 29.8 yuan. Haier Biotech’s current latest total market value is 9,865 million yuan; it ranks 35/129 in the medical devices sector by market value, and ranks 1915/5193 among the A-shares of both markets.

Regarding capital flow data, this week Haier Biotech’s main fund had a total net outflow of 2.3269 million yuan, the funds for “proprietary funds” had a total net inflow of 2.481 million yuan, and retail investors’ funds had a total net outflow of 0.1542 million yuan. A detailed view of this week’s capital flows is shown in the table below:

The company’s main indicators and rankings within the industry are as follows:

In the past three months, Haier Biotech’s financing net outflow was 4.1038 million yuan, and the financing balance decreased; securities lending net outflow was 2.48M, and the securities lending balance decreased.

Haier Biotech (688139) principal business: targeting the best user experience for creators, and serving life science users such as pharmaceutical companies, universities, and research institutions, as well as medical and public health users including hospitals, CDCs, blood centers, and grassroots public health, to provide comprehensive digital solution packages represented by smart laboratories, digital hospitals, smart public health, and smart blood use. The 2025 annual report of Haier Biotech shows that for the year, the company’s main operating revenue was 46.18M yuan, up 1.96% year-on-year; net profit attributable to the parent was 251 million yuan, down 31.61% year-on-year; net profit after deducting non-recurring items was 220 million yuan, down 31.74% year-on-year. Of this, in the fourth quarter of 2025, the company’s main operating revenue for the single quarter was 567 million yuan, up 13.09% year-on-year; net profit attributable to the parent for the single quarter was 52.3399 million yuan, down 8.96% year-on-year; net profit after deducting non-recurring items for the single quarter was 27.31M yuan, up 1.32% year-on-year. The asset-liability ratio was 20.17%; investment income was 27.309 million yuan; financial expenses were -25.8781 million yuan; gross margin was 46.79%.

The above content is compiled by Star Market News from publicly available information and generated by an AI algorithm (filing number for cybersecurity and information services 310104345710301240019). It does not constitute an investment recommendation.